Treatment with ISD017 and CYC reduced the mortality of Fcgr2b-deficient lupus mice with a comparable survival rate, suggesting that ISD017 could be a therapeutic drug for SLE. This evidence concerns the gene FCGR2B and systemic lupus erythematosus.